Schrödinger, Inc.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, May 19, 2021

The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company\xe2\x80\x99s 2021 Inducement Equity Incentive Plan.\nSchr\xc3\xb6dinger is transforming the way therapeutics and materials are discovered.

Key Points: 
  • The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company\xe2\x80\x99s 2021 Inducement Equity Incentive Plan.\nSchr\xc3\xb6dinger is transforming the way therapeutics and materials are discovered.
  • Schr\xc3\xb6dinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods.
  • The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world.
  • To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210519005108/en/\n'

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, April 16, 2021

The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company\xe2\x80\x99s 2021 Inducement Equity Incentive Plan.\nSchr\xc3\xb6dinger is transforming the way therapeutics and materials are discovered.

Key Points: 
  • The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company\xe2\x80\x99s 2021 Inducement Equity Incentive Plan.\nSchr\xc3\xb6dinger is transforming the way therapeutics and materials are discovered.
  • Schr\xc3\xb6dinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods.
  • The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world.
  • To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210416005046/en/\n'

Schrödinger to Participate in BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery

Retrieved on: 
Friday, April 9, 2021

Schrdinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that Ramy Farid, Ph.D., chief executive officer at Schrdinger, will participate in a panel during the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery.

Key Points: 
  • Schrdinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that Ramy Farid, Ph.D., chief executive officer at Schrdinger, will participate in a panel during the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery.
  • Schrdinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods.
  • Schrdingers multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
  • Founded in 1990, Schrdinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries.

Schrödinger to Participate in Credit Suisse 2021 Healthcare Innovators Series: The Intersection of Drug Discovery, Drug Development and Artificial Intelligence

Retrieved on: 
Wednesday, March 17, 2021

Schrdinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that Ramy Farid, Ph.D., chief executive officer at Schrdinger, will participate in a panel during the Credit Suisse 2021 Healthcare Innovators Series: The Intersection of Drug Discovery, Drug Development and Artificial Intelligence.

Key Points: 
  • Schrdinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that Ramy Farid, Ph.D., chief executive officer at Schrdinger, will participate in a panel during the Credit Suisse 2021 Healthcare Innovators Series: The Intersection of Drug Discovery, Drug Development and Artificial Intelligence.
  • Schrdinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods.
  • Schrdingers multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
  • Founded in 1990, Schrdinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries.

Schrödinger to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 10, 2020

Schrdinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that members of the management team will participate in the upcoming virtual investor conferences in November and December.

Key Points: 
  • Schrdinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that members of the management team will participate in the upcoming virtual investor conferences in November and December.
  • ET
    Live webcasts of the fireside chats can be accessed under "News & Events" in the investors section of Schrdingers website https://ir.schrodinger.com/news-and-events/event-calendar .
  • Schrdinger is transforming the way therapeutics and materials are discovered.
  • Founded in 1990, Schrdinger has over 400 employees and is engaged with customers and collaborators in more than 70 countries.

Schrödinger to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, September 8, 2020

Schrdinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that members of the management team will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 12:30 p.m.

Key Points: 
  • Schrdinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that members of the management team will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 12:30 p.m.
  • A live webcast of the presentation can be accessed under "News & Events" in the investors section of Schrdingers website https://ir.schrodinger.com/news-and-events/event-calendar .
  • Schrdinger is deeply committed to investing in the science and talent that drive its computational platform.
  • Schrdinger was founded in 1990, has over 400 employees and is engaged with customers and collaborators in more than 70 countries.